m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0185)
Name
Traumatic brain injury induced by controlled cortical impact injury
ICD
ICD-11: NA07
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 2 item(s) under this disease
Crosstalk ID: M6ACROT05082
 Crosstalk Info 
m6A Regulator Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)
 Regulator Info 
m6A Target NAD-dependent protein deacetylase sirtuin-2 (SIRT2)
 Target Gene 
Epigenetic Regulator Maternally expressed 3 (MEG3)
Regulated Target Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05651
 Crosstalk Info 
m6A Regulator Fat mass and obesity-associated protein (FTO)
 Regulator Info 
m6A Target microRNA 155 (MIR155)
 Target Gene 
Epigenetic Regulator MicroRNA 155 (MIR155)
Crosstalk relationship m6A → ncRNA
References
Ref 1 Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465.
Ref 2 Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. doi: 10.1038/nrd2940.
Ref 3 Sirukumab: A Potential Treatment for Mood Disorders?. Adv Ther. 2017 Jan;34(1):78-90. doi: 10.1007/s12325-016-0455-x. Epub 2016 Dec 2.
Ref 4 The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
Ref 5 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. doi: 10.2337/diabetes.52.3.588.
Ref 6 Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90.